CONCORDBIO price chart
Daily close · 5-year history
Instrument details
Identifiers & classification
- Symbol
- CONCORDBIO
- MB Code
- MBEQU2922
- ISIN
- INE338H01029
- BSE code
- 543960
- Industry group
- Pharmaceuticals & Biotechnology
- Screener
- View peers →
Latest earnings
Most recent declared quarter
- Quarter
- Mar 2026
- Revenue
- 326.08 Cr
- Net profit
- 88.47 Cr
- EPS
- 8.46
- YoY revenue
- -24.15%
Company documents
11 PDFs across 4 categories
Audited annual reports & financial statements
Earnings call transcripts & Q&A
Investor decks & strategy updates
Exchange filings & corporate announcements
Corporate timeline
Earnings, news & corporate actions for CONCORDBIO
Concord Biotech rose 5% after USFDA approved its ANDA for Tofacitinib Tablets in 5 mg and 10 mg strengths, opening access to a US market …
Concord Biotech's Q4 net profit fell 36.8% to ₹88.8 crore, revenue dropped 24.1%, EBITDA margin shrank, and the board recommended a ₹7.55…
EPS 6.39 vs est. 7.96
Missed estimates by 19.68%
EPS 6.03 vs est. 5.00
Beat estimates by 20.65%
Dividend of ₹10.70 per share
Ex-date corporate action
Concord Biotech's standalone net profit fell 26.91% to Rs 42.57 crore in Q2 June 2025, down from Rs 58.24 crore in the previous quarter.
As of July 7, 2025, Concord Biotech's market capitalization is ₹18,431.80 Cr. The 52-week high is ₹2,658.00, with the low not specified. …
Price returns
Historical performance
Technicals
Indicator consensus